Pritelivir mesylate is under clinical development by AiCuris Anti-infective Cures and currently in Phase III for Simplexvirus (HSV) Infections.

Gimatecan is under clinical development by Lee's Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer.

Remimazolam (Anerem, Byfavo, Ruima) is a benzodiazepine derivative, acts as a sedating agent. It is formulated as powder for solution for intravenous route of administration. Remimazolam is indicated ...

Yttrium 90-labelled edotreotide is under clinical development by Progenics Pharmaceuticals and currently in Phase II for Neuroblastoma.

Pimavanserin tartrate is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Autism Spectrum Disorder (ASD).

Bezisterim is under clinical development by BioVie and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 12% phase transition ...

Bezisterim is under clinical development by BioVie and currently in Phase II for Mild Cognitive Impairment. According to GlobalData, Phase II drugs for Mild Cognitive Impairment does not have ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Liposarcoma. According to GlobalData, Phase II drugs for Liposarcoma have a 33% phase transition success rate ...

Cediranib maleate is under clinical development by AstraZeneca and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Uterine Cancer.